

Can the FDA Salvage Interchangeable Follow-On Biologics?

November 19, 2019

ATTORNEYS

Mathias, Ted Ropka, PhD, Stacie

PRACTICE AREAS

Biotechnology FDA Ted Mathias and Stacie Ropka, PhD BioProcess Online / Biosimilar Development

BioProcess Online and Biosimilar Development published "Can the FDA Salvage Interchangeable Follow-On Biologics?", an article co-written by Axinn partners Ted Mathias and Stacie Ropka.